Eras­ca delves fur­ther in­to RAS/MAPK with No­var­tis drug, prices $100M of­fer­ing

Af­ter re­ceiv­ing feed­back on piv­otal stud­ies from Eu­ro­pean reg­u­la­tors, but not yet the FDA, No­var­tis is out-li­cens­ing a pan-RAF in­hibitor go­ing af­ter tu­mors ex­cit­ed by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER